Alung
AcquiredPittsburgh, US · 3,583 employees on LinkedIn · 4 known investors
Find your way into Alung
Sign up to see every warm intro you have to Alung
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Alung team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
LivaNova develops medical devices and therapies aimed at treating conditions such as epilepsy (seizures), sleep disorders, depression, and cardiac conditions. It operates in the medical technology industry, serving patients and healthcare providers.
Founders & leadership
PM
Peter M. DeComoExecutive
DJ
David J. HaffnerExecutive
NJ
Nicholas J KuhnExecutive
Board
DL

JM

JJ
Joseph J Stevens IIIBoard director
GG
Gary G. GlausserBoard director
KJ
Kraig J. McEwenBoard director
GE
Gerald E. McGinnisBoard director
NE
Nicholas E. CullenBoard director
WB
William B RossBoard director
Investors · 4
Allos Ventureslisted by Allos VenturesCincinnati · $1M – $6M
How we know: board seat on SEC Form D · the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$101.3M disclosed across 12 rounds · 2011–2021
▶$4.6MraisedAug 2021 · 55 investors · BiotechnologyRule 506(b)
▶$4.6MraisedAug 2021 · 55 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam G. SeiverDirector
- Jeanne CunicelliDirector
- David MotleyDirector
- Gary G. GlausserDirector
- Peter M. DeComoExecutive Officer, Director
- John KuzmishinDirector
- David J. HaffnerExecutive Officer
- Offering amount
- $12M
- Amount sold
- $4.6M
- Sales commissions
- $12K
- Placement agents
- Weild & Co.
- First sale
- May 2021
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$5.4MraisedNov 2020 · 47 investors · BiotechnologyRule 506(b)
▶$5.4MraisedNov 2020 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeanne CunicelliDirector
- Adam G. SeiverDirector
- John KuzmishinDirector
- Peter M. DeComoExecutive Officer, Director
- David MotleyDirector
- Kraig J. McEwenDirector
- Gary G. GlausserDirector
- David J. HaffnerExecutive Officer
- Offering amount
- $15M
- Amount sold
- $5.4M
- First sale
- Oct 2020
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$2MraisedJun 2020 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedJun 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam G. SeiverDirector
- Jeanne CunicelliDirector
- David MotleyDirector
- Gary G. GlausserDirector
- Peter M. DeComoExecutive Officer, Director
- Kraig J. McEwenDirector
- John KuzmishinDirector
- David J. HaffnerExecutive Officer
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- May 2020
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$3.3MraisedFeb 2020 · 52 investors · BiotechnologyRule 506(b)
▶$3.3MraisedFeb 2020 · 52 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter M. DeComoExecutive Officer, Director
- David MotleyDirector
- Kraig J. McEwenDirector
- Adam G. SeiverDirector
- David J. HaffnerExecutive Officer
- Jeanne CunicelliDirector
- Gary G. GlausserDirector
- Offering amount
- $5M
- Amount sold
- $3.3M
- First sale
- Jan 2020
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$3MraisedFeb 2020 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedFeb 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter M. DeComoExecutive Officer, Director
- David MotleyDirector
- Kraig J. McEwenDirector
- Adam G. SeiverDirector
- David J. HaffnerExecutive Officer
- Jeanne CunicelliDirector
- Gary G. GlausserDirector
- Offering amount
- $3M
- Amount sold
- $3M
- Sales commissions
- $180K
- Placement agents
- Kee Colen
- First sale
- Feb 2020
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$5MraisedAug 2019 · 48 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2019 · 48 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John E. McIlwraithDirector
- Gary G. GlausserDirector
- Kraig J. McEwenDirector
- David MotleyDirector
- Peter M. DeComoExecutive Officer, Director
- David J HaffnerExecutive Officer
- Adam SeiverDirector
- Jeanne CunicelliDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Aug 2019
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$5MraisedJan 2019 · 61 investors · BiotechnologyRule 506(b)
▶$5MraisedJan 2019 · 61 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeanne CunicelliDirector
- Kraig J. McEwenDirector
- Peter M. DeComoExecutive Officer, Director
- Gerald E. McGinnisDirector
- Adam SeiverDirector
- Gary G. GlausserDirector
- David J. HaffnerExecutive Officer
- John E. McIlwraithDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Dec 2018
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
▶$37.5MraisedDec 2017 · 96 investors · BiotechnologyRule 506(b)
▶$37.5MraisedDec 2017 · 96 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David J. HaffnerExecutive Officer
- John McIlwraithDirector
- Gary G. GlausserDirector
- Adam SeiverDirector
- Jeanne CunicelliDirector
- Peter M. DeComoExecutive Officer, Director
- Gerald E. McGinnisDirector
- Kraig J. McEwenDirector
- Offering amount
- $42.6M
- Amount sold
- $37.5M
- Sales commissions
- $1.5M
- Placement agents
- Kee Colen
- First sale
- Mar 2017
- Incorporated
- Corporation, Pennsylvania
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Alung do?
- LivaNova develops medical devices and therapies aimed at treating conditions such as epilepsy (seizures), sleep disorders, depression, and cardiac conditions. It operates in the medical technology industry, serving patients and healthcare providers.
- Who are Alung's investors?
- Alung's investors include Allos Ventures, Birchmere Ventures, Riverfront Ventures, LLC, Black Tech Nation Ventures.
- How much funding has Alung raised?
- Alung has disclosed $101.3M raised across 12 rounds.
- Where is Alung headquartered?
- Alung is headquartered in Pittsburgh, US.


